Welcome to our dedicated page for Bachem Holding news (Ticker: BCHMY), a resource for investors and traders seeking the latest updates and insights on Bachem Holding stock.
The Bachem Holding AG (BCHMY) news page on Stock Titan aggregates company announcements and market-relevant updates for investors following this ADR. Bachem, whose primary listing is on the SIX Swiss Exchange, describes itself as a specialist in the development and manufacture of peptides and oligonucleotides, supplying pharmaceutical and biotechnology companies worldwide from its headquarters in Switzerland and sites in Europe, the US, and Asia.
News about Bachem frequently covers financial results, such as half-year and full-year sales, EBITDA margins, and performance by product category including Commercial API, CMC Development, and Research & Specialties. These releases often discuss demand trends for peptide and oligonucleotide projects, operational execution across the company’s manufacturing network, and guidance for future growth in local currencies.
Another recurring theme in Bachem’s news is capacity expansion. Updates describe progress on Building “K” in Bubendorf, which the company calls its most advanced and largest production plant for large volumes of peptides and oligonucleotides, as well as plans for a new manufacturing site in Sisslerfeld. Announcements also highlight investments in U.S. sites at Vista and Torrance and in Vionnaz in Western Switzerland.
Corporate governance and leadership developments are also reported, including Annual General Meeting outcomes, dividend decisions, changes to the Board of Directors, and adjustments to the Corporate Executive Committee and COO role. By reviewing this news feed, readers can follow how Bachem communicates its strategy, investment program, and operational milestones that affect its position as a peptide and oligonucleotide manufacturer.
Bachem (OTC: BCHMY) announced that Chief Commercial Officer Torsten Wöhr will leave the company and that CEO Anne-Kathrin Stoller will assume CCO duties in addition to her CEO role effective May 25, 2026. The company thanked Wöhr for his contributions to the oligonucleotide and peptide businesses and emphasized continuity in customer relationships during the transition.
Bachem (SIX: BANB) held its Annual General Meeting 2026 where shareholders approved all board proposals. A dividend of CHF 0.90 per share was approved, payable on May 6, 2026; last trading day with entitlement is April 30, 2026 and shares trade ex-dividend as of May 4, 2026.
Attendance was 78.3% of 74,977,940 eligible shares. Board members were re-elected; Helma Wennemers was newly elected Chair of the Compensation Committee. Forvis Mazars SA, Zurich was appointed auditor for 2026. A full list of resolutions and the financial calendar were published.
Bachem (OTC: BCHMY) closed a CHF 500 million revolving credit facility with a five-year maturity and a non-committed option to increase by CHF 150 million. UBS Switzerland AG acted as lead arranger and agent with a consortium of domestic and international banks. The financing refinances existing bilateral credit lines and is intended to support Bachem's strategic growth initiatives while strengthening operational and financial flexibility.
Bachem (OTC: BCHMY) reported group sales of CHF 695.1 million in 2025, up 14.8% (+19.2% in local currencies), and EBITDA of CHF 214.7 million (+21.8%), yielding an EBITDA margin of 30.9% (adjusted 28.6%).
The board proposes raising the dividend to CHF 0.90 per share. Investments totaled CHF 332.6 million in 2025 and CAPEX above CHF 400 million is planned for 2026. Outlook: sales growth of 35–45% in LC and an EBITDA margin in the low thirties (LC) for 2026.
Bachem (SIX: BANB) announced that Anne-Kathrin Stoller will become CEO effective January 1, 2026, succeeding Thomas Meier, who is leaving after more than thirty years with the company and nearly six years as CEO.
Stoller has worked at Bachem since 2006, has held roles including Head of Business Development & Sales Europe, Chief Marketing Officer, and since 2022 has led Bachem Americas as Chief Operating Officer Americas; she holds a doctorate in bioorganic chemistry from the University of Basel.
Bachem (OTC:BCHMY) reported progress on two capacity projects: the inspection and planned start-up of Building K in Bubendorf and an adjacent property acquisition in Vista, California. Local regulators inspected Building K and signaled no delays; Bachem expects first GMP batches in 2025 with commercial ramp in 2026 while remaining construction continues. In the US, the company plans to convert the Vista property to production and announced an overall ~USD 250 million investment for 2026–2030 to expand Vista capacity and modernize Torrance.
Bachem (OTC:BCHMY) has announced the appointment of Hans Van Hees as Chief Operations Officer (COO), effective September 1, 2025. Van Hees, currently serving as COO Europe, will join the Corporate Executive Committee and oversee Bachem's worldwide manufacturing network.
Van Hees joined Bachem in 2024 from Pharma Resource Group and brings over 25 years of manufacturing leadership experience from Johnson & Johnson and Janssen. He will take over the COO responsibilities from CEO Thomas Meier, who had been handling both roles since 2023. The new COO holds a PhD in Chemistry and an MBA from KU Leuven.
Bachem (OTC:BCHMY) reported robust financial results for H1 2025, with sales reaching CHF 313.0 million, marking a significant increase of 30.2% (34.1% in local currencies) compared to the prior year. The company's EBITDA surged 64% to CHF 91.0 million, with margin expanding to 29.1% from 23.1%.
Commercial API sales grew 32.4% to CHF 168.4 million, while Clinical Development revenue increased 36.9% to CHF 123.7 million. The company has raised its 2025 guidance to 13-18% sales growth and invested CHF 129.1 million in capacity expansion during H1.
Looking ahead, Bachem aims to achieve annual sales exceeding CHF 1 billion and an EBITDA margin over 30% by 2026, supported by significant investments including the new Building K facility and planned expansion in Sisslerfeld.
Bachem held its Annual General Meeting 2025 with strong shareholder participation of 79.7% of eligible shares. The meeting approved a dividend of CHF 0.85 per share, payable on May 7, 2025, with ex-dividend trading starting May 5, 2025.
Key approvals included the re-election of the Chairman and Board members, with Dr. Simone Wyss Fedele joining as a new board member. Shareholders endorsed the annual report, financial statements, sustainability report, and remuneration report. Forvis Mazars SA was appointed as the new auditor for 2025.
The company's upcoming financial calendar includes:
- Dividend payout: May 7, 2025
- Half-Year Report 2025: July 24, 2025
- Annual Report 2025: March 12, 2026
- Next Annual General Meeting: April 29, 2026